Capstone Therapeutics (NASDAQ:CAPS) Stock Price Down 4.2% – Time to Sell?

Capstone Therapeutics Corp. (NASDAQ:CAPS)’s stock price dropped 4.2% during trading on Tuesday . The stock traded as low as $0.5689 and last traded at $0.5830. Approximately 106,616 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 203,225 shares. The stock had previously closed at $0.6083.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Capstone Therapeutics Price Performance

The stock’s 50-day moving average is $0.74 and its 200 day moving average is $1.05. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The company has a market cap of $4.84 million, a PE ratio of -0.61 and a beta of -1.21.

Capstone Therapeutics (NASDAQ:CAPS) last issued its quarterly earnings results on Tuesday, November 18th. The company reported ($0.35) earnings per share (EPS) for the quarter. Capstone Therapeutics had a negative return on equity of 29.50% and a negative net margin of 12.40%.The business had revenue of $13.65 million for the quarter.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned 0.40% of Capstone Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.